Mineralys Therapeutics, Inc. (MLYS) PT Raised to $52 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MLYS Hot Sheet
Price: $21.12 -1.22%
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 16
Rating Summary:
10 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 24 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Matthew Caufield raised the price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) to $52.00 (from $42.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Kymera Therapeutics (KYMR) PT Raised to $132 at Brookline Capital Markets
- HSBC Upgrades FedEx (FDX) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
